Regulation of Cell and Gene Therapy Medicinal Products in Taiwan

Abstract

Owing to the rapid and mature development of emerging biotechnology in the fields of cell culture, cell preservation, and recombinant DNA technology, more and more cell or gene medicinal therapy products have been approved for marketing, to treat serious diseases which have been challenging to treat with current medical practice or medicine. This chapter will briefly introduce the Taiwan Food and Drug Administration (TFDA) and elaborate regulation of cell and gene therapy medicinal products in Taiwan, including regulatory history evolution, current regulatory framework, application and review procedures, and relevant jurisdictional issues. Under the promise of quality, safety, and efficacy of medicinal products, it is expected the regulation and environment will be more flexible, streamlining the process of the marketing approval of new emerging cell or gene therapy medicinal products and providing diverse treatment options for physicians and patients.

Keywords: Cell therapy medicinal products; Clinical trials; Gene therapy medicinal products; Investigational New Drug (IND); Medical practice; Medicinal products; New Drug Application (NDA); New medical practice; Points to consider; TFDA Guidance; Taiwan Food and Drug Administration (TFDA).